{"id":53884,"date":"2026-01-13T13:43:51","date_gmt":"2026-01-13T05:43:51","guid":{"rendered":"https:\/\/flcube.com\/?p=53884"},"modified":"2026-01-13T13:43:52","modified_gmt":"2026-01-13T05:43:52","slug":"scineuro-pharmaceuticals-licenses-alzheimers-bbb-antibody-platform-to-novartis-in-1-5-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53884","title":{"rendered":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>SciNeuro Pharmaceuticals<\/strong> announced a <strong>global collaboration<\/strong> with <strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a>) to advance its <strong>next\u2011generation amyloid beta\u2011targeting antibody program<\/strong> incorporating proprietary <strong>blood\u2011brain barrier (BBB) shuttle technology<\/strong> for the treatment of <strong>Alzheimer\u2019s disease (AD)<\/strong>. The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>SciNeuro Pharmaceuticals &amp; Novartis AG (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>Amyloid beta\u2011targeting antibody with BBB shuttle<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Alzheimer\u2019s disease (AD)<\/td><\/tr><tr><td><strong>Collaboration Scope<\/strong><\/td><td>Joint early\u2011development; Novartis assumes global development &amp; commercialization post\u2011Phase\u202fI\/IIa<\/td><\/tr><tr><td><strong>Transaction Closing<\/strong><\/td><td>H1\u202f2026 (expected)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 165\u202fmillion (cash)<\/td><\/tr><tr><td><strong>Research Funding<\/strong><\/td><td>Fully funded R&amp;D through early\u2011development phase<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to USD 800\u202fmillion (undisclosed triggers)<\/td><\/tr><tr><td><strong>Regulatory Milestones<\/strong><\/td><td>Up to USD 400\u202fmillion (approval\u2011based)<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Up to USD 300\u202fmillion (sales\u2011based)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to USD 1.5\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, mid\u2011single\u2011digit to low\u2011double\u2011digit percentages on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Innovation:<\/strong> Proprietary <strong>BBB shuttle technology<\/strong> that enhances antibody transcytosis into the CNS, achieving <strong>3\u20115\u00d7 higher brain penetration<\/strong> vs. conventional anti\u2011amyloid antibodies<\/li>\n\n\n\n<li><strong>Candidate Antibodies:<\/strong> Novel clones identified via <strong>humanized mouse models<\/strong>; demonstrate reduced microhemorrhage risk in preclinical studies<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Potential for <strong>lower infusion\u2011related reactions<\/strong> and <strong>reduced ARIA\u2011E frequency<\/strong> compared to existing therapies (aducanumab, lecanemab)<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> SciNeuro\u2019s Suzhou GMP facility validated for 5,000\u202fL scale; tech transfer to Novartis planned Q3\u202f2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-revenue-outlook\">Market Opportunity &amp; Revenue Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Alzheimer\u2019s Market<\/strong><\/td><td>$7.2\u202fbillion<\/td><td>$9.5\u202fbillion<\/td><td>$12.3\u202fbillion<\/td><\/tr><tr><td><strong>Anti\u2011Amyloid Share<\/strong><\/td><td>35\u202f%<\/td><td>42\u202f%<\/td><td>48\u202f%<\/td><\/tr><tr><td><strong>BBB\u2011Enhanced Antibody Niche<\/strong><\/td><td>0\u202f%<\/td><td>5\u202f%<\/td><td>12\u202f%<\/td><\/tr><tr><td><strong>SciNeuro Royalty Forecast<\/strong><\/td><td>\u2013<\/td><td>$48\u202fmillion<\/td><td>$118\u202fmillion<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td>$1.8\u202fbillion (2035E)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Eisai\/Biogen\u2019s Leqembi<\/strong> (lecanemab) and <strong>Eli Lilly\u2019s Kisunla<\/strong> (donanemab) dominate IV anti\u2011amyloid market<\/li>\n\n\n\n<li><strong>SciNeuro\u2019s BBB shuttle<\/strong> may enable <strong>lower dosing<\/strong>, <strong>monthly subcutaneous delivery<\/strong>, and <strong>improved safety profile<\/strong>\u2014key differentiators for market penetration<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong><\/li>\n\n\n\n<li>Deal validates SciNeuro\u2019s <strong>CNS delivery platform<\/strong>, potentially unlocking <strong>future collaborations<\/strong> in Parkinson\u2019s disease and ALS<\/li>\n\n\n\n<li>Novartis gains <strong>first\u2011mover advantage<\/strong> in next\u2011generation anti\u2011amyloid space, complementing its <strong>U.S. Neurology franchise<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><\/tr><\/thead><tbody><tr><td><strong>IND Filing<\/strong><\/td><td>Q3\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202fI Initiation<\/strong><\/td><td>Q1\u202f2027<\/td><\/tr><tr><td><strong>Phase\u202fIIa POC<\/strong><\/td><td>Q4\u202f2028<\/td><\/tr><tr><td><strong>Phase\u202fIII Start<\/strong><\/td><td>H2\u202f2029<\/td><\/tr><tr><td><strong>Regulatory Submission<\/strong><\/td><td>2031\u202fE<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SciNeuro\u2019s BBB technology efficacy, Novartis development plans, and projected royalty streams. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[140,865,2989],"class_list":["post-53884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-novartis","tag-nyse-nvs","tag-scineuro-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53884\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal\" \/>\n<meta property=\"og:description\" content=\"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53884\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T05:43:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T05:43:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal\",\"datePublished\":\"2026-01-13T05:43:51+00:00\",\"dateModified\":\"2026-01-13T05:43:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1302.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"SciNeuro Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53884#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53884\",\"name\":\"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1302.webp\",\"datePublished\":\"2026-01-13T05:43:51+00:00\",\"dateModified\":\"2026-01-13T05:43:52+00:00\",\"description\":\"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53884\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1302.webp\",\"width\":1080,\"height\":608,\"caption\":\"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53884#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal - Insight, China&#039;s Pharmaceutical Industry","description":"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53884","og_locale":"en_US","og_type":"article","og_title":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal","og_description":"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.","og_url":"https:\/\/flcube.com\/?p=53884","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T05:43:51+00:00","article_modified_time":"2026-01-13T05:43:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53884#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53884"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal","datePublished":"2026-01-13T05:43:51+00:00","dateModified":"2026-01-13T05:43:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53884"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","keywords":["Novartis","NYSE: NVS","SciNeuro Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53884#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53884","url":"https:\/\/flcube.com\/?p=53884","name":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53884#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","datePublished":"2026-01-13T05:43:51+00:00","dateModified":"2026-01-13T05:43:52+00:00","description":"SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE:\u202fNVS) to advance its next\u2011generation amyloid beta\u2011targeting antibody program incorporating proprietary blood\u2011brain barrier (BBB) shuttle technology for the treatment of Alzheimer\u2019s disease (AD). The transaction positions SciNeuro as a key innovation partner in CNS drug delivery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53884#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53884"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53884#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","width":1080,"height":608,"caption":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53884#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SciNeuro Pharmaceuticals Licenses Alzheimer\u2019s BBB Antibody Platform to Novartis in $1.5\u202fBillion Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53884"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53884\/revisions"}],"predecessor-version":[{"id":53887,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53884\/revisions\/53887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53886"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}